<?xml version="1.0" encoding="UTF-8"?>
<p>Diverse antiviral drugs with proven activity against influenza virus, SARS or MERS coronaviruses have been investigated for the treatment of COVID-19, alone or in combination with other drugs (anti-parasitic agents, anti-inflammatory drugs). Of these, remdesivir has been approved by the FDA for emergency use in adults and children hospitalized with severe, suspected or laboratory-confirmed COVID-19. Moreover, the NIH panel recommends remdesivir for treatment of COVID-19 in patients who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [
 <xref rid="B2-ijms-21-05559" ref-type="bibr">2</xref>]. Dexamethasone treatment showed promising results in reducing the 28-day mortality in intubated patients and in cases receiving oxygen. The WHO reported that it could be lifesaving for critically ill COVID-19 patients and the NIH panel recommends using dexamethasone at proven doses in COVID-19 patients who are mechanically ventilated, as well as in patients who require supplemental oxygen but are not mechanically ventilated [
 <xref rid="B2-ijms-21-05559" ref-type="bibr">2</xref>].
</p>
